Navigation Links
RSB Spine, LLC Announces First Implantation of the InterPlate(TM) L for the Lumbar Spine
Date:1/16/2008

CLEVELAND, Jan. 16 /PRNewswire/ -- RSB Spine, LLC, today announced the first implantation of its proprietary InterPlate(TM) L in the lumbar spine. The InterPlate L was approved as an interbody device in September 2007. The unique design offers a number of advantages over current devices. In addition, RSB Spine has recently completed the national rollout of its InterPlate C device for use in the cervical spine, which is being very well received by spine surgeons across the United States. The company also expects to introduce two new InterPlate products manufactured from a radiolucent polymer (PEEK, polyetheretherketone) later this year.

Fusion is one of the most common spinal procedures performed by neurosurgeons and orthopedic spine surgeons. The InterPlate C and InterPlate L are designed to facilitate rapid fusion and are used in conjunction with graft material to fuse spinal vertebrae.

Robert S. Bray, Jr., M.D., the inventor of the InterPlate and the first to use the lumbar version, said: "The InterPlate L simplifies the implant procedure and provides a very low profile implant with secure anti-backout protection of the screws for safety under the great vessels. It is a next generation from anterior lumbar plates, with the versatility for all levels."

RSB Spine Chief Executive Officer John A. Redmond said: "Today's announcement marks yet another milestone for our InterPlate family of products. Featuring a one-of-a-kind design and ease of insertion, the InterPlate L is expected to be highly attractive to many spine surgeons, as well as very competitive with other devices currently in the marketplace."

Redmond continued: "The InterPlate L has been exhibited at a number of spine meetings and the response has been gratifying, with many surgeons anxious to utilize this new device when released nationally."

RSB Spine is a privately held medical device company focused on developing innovative spinal implants. In 2004, RSB Spine sold its surgical instrument line to Jarit, an Integra LifeSciences Holding Corp. company and, in 2005, sold its cervical plate system to NuVasive, Inc.


'/>"/>
SOURCE RSB Spine, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... Microbial genomics leader ... grant award has been made to Dr. Renato Polimanti of Yale University School ... the oral microbiome. Grant proposals have been vetted by the company’s scientific review ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation ... and lumbar disc production, company President, Jake Lubinski will be traveling to Switzerland ... AxioMed disc in Bern, Lucerne, and Zurich to discuss the benefits of a ...
(Date:12/2/2016)... , Dec. 2, 2016 Amgen (NASDAQ: ... ) today announced the submission of a Marketing Authorization Application ... a biosimilar candidate to Avastin ® (bevacizumab). The companies ... to the EMA. "The submission of ABP ... seeks to expand our oncology portfolio," said Sean E. ...
(Date:12/2/2016)... ... 01, 2016 , ... ACEA Biosciences, Inc. announced today that it will be ... at the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December ... clinical trials for AC0010 in patients with advanced non-small cell lung cancer harboring the ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
Breaking Biology News(10 mins):